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Background
Anticoagulation with oral vitamin K antagonists (VKA) is very important in
patients supported on a left ventricular assist device (LVAD) to prevent
thromboembolic complications. Some patients tolerate VKAs poorly and have an
unstable INR as a result. It is reported that low-dose vitamin K can improve INR
control in patients with an unstable INR in other clinical settings. We evaluated its
safety and effectiveness in patients on LVAD support.
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The records of all patients supported on an implantable LVAD between January,
2013 and March, 2014 were reviewed retrospectively to identify those who had
received low-dose vitamin K while on warfarin. INR values and warfarin doses
before and after initiation of vitamin K supplementation were compared to
evaluate its effectiveness.
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Results
There were six LVAD patients who were on low-dose vitamin K due to an
unstable INR out of a total of 59 VAD patients followed as an outpatient. The
standard deviation (SD) of INR decreased significantly after starting vitamin K
(p=0.04) while the SD of warfarin dose did not (p=0.22). Comparing divergence
from target INR, INR became significantly closer to target INR after starting
vitamin K. The number of bleeding complications tended to be fewer on vitamin
K, but this did not reach statistical significance (p=0.09).
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Conclusions
Daily low-dose vitamin K supplementation can improve INR control in LVAD
patients with unstable INR without increasing thromboembolic complications.
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Introduction
Appropriate anticoagulation is important in the management of patients on left
ventricular assisting device (LVAD) support.1 A stable level of anticoagulation is
desired to minimize anticoagulation-related morbidity.2, 3 However, the degree of
anticoagulation produced by vitamin K antagonists, such as warfarin, depends on
various factors.4 Maintaining an appropriate international normalization ratio
(INR) often requires frequent blood tests and changes in the warfarin dosage.
One cause of INR instability is insufficient daily vitamin K intake. 5 There are
several reports of achieving a stable INR by adding low-dose vitamin K in
patients with an unstable INR in those who have atrial fibrillation or other
common needs for anticoagulation. 5 However, data on low-dose vitamin K in
LVAD patients are lacking. Therefore, we evaluated the effectiveness of lowdose vitamin K to achieve stability in LVAD patients with an unstable INR.

Methods
The records for all patients on long-term support with a continuous flow LVAD
and followed at Thomas Jefferson University Hospital between January 1, 2013
and March 31, 2014 were reviewed to identify those patients who were being
treated with low-dose oral vitamin K due to an unstable INR. There were no
specific criteria for the definition of an unstable INR. Vitamin K initiation was at
the discretion of the treating physicians. Vitamin K tablets (100 mcg) were
obtained by the patients as a dietary supplement at retail stores. Data on the INR
and warfarin dosing were collected up to three months before and after initiation
of vitamin K supplementation, reviewing patient charts retrospectively. When
vitamin K was started during the implant hospital admission, data during the
admission were used in addition to outpatient data to complete the three-month
follow-up. When vitamin K was started during outpatient follow up, outpatient
data were used. In order to compare the degree of INR control before and after
initiation of vitamin K supplementation, three factors were evaluated statistically.
Firstly, the variance of INR and warfarin doses was compared using F-test, since
significantly smaller variance would suggest better control. Secondly, differences
between measured INR and median of target INR range (divergence) were
compared using Student’s t-test. Smaller divergence indicates INR closer to
target, proving better INR control. Lastly, average INR and warfarin doses were
also compared to evaluate impact of vitamin K on actual INR values and warfarin
dosage. The INR goal range was individualized for each patient and was based
on clinical risk factors for thrombosis or hemorrhage, as well as prior thrombotic
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or bleeding events. Complications from anticoagulation including bleeding and
thromboembolic event were also evaluated.

Results
There were six LVAD patients who were on low-dose vitamin K due to an
unstable INR out of a total of 59 VAD patients followed as an outpatient. In
general, the patients had a labile INR, with values well above the therapeutic
range on minimal warfarin, or fluctuating between supra-therapeutic and subtherapeutic despite changes in warfarin dosing. Table 1 shows INR and warfarin
doses of each patient before and after the initiation of vitamin K. The variance of
INR was significantly smaller in five of six cases (83%) after initiation of vitamin
K. The average INR decreased significantly in two of six cases (33%).
Differences between measured INR and median of target INR range (divergence)
were significantly better in three of six cases (50%) after initiation of vitamin K.
The average warfarin dose decreased significantly in one case but was not
significantly different in other cases. In three of the patients, the average INR was
below the lower end of the individualized target range after initiation of vitamin K,
but the range of INR values obtained were narrower, corresponding to the
improved divergence seen.
Table 2 shows averages of six patients and comparison of each before and after
initiation of vitamin K. Average number of complications during follow up periods
is also shown. The SD of INR decreased significantly after initiation of vitamin K
(p=0.04) while the SD of warfarin doses did not (p=0.22). Comparing divergence
of unstable patients before and after vitamin K, INR became significantly closer
to target INR after initiation of vitamin K. None of the patients had
thromboembolic complications after being started on vitamin K, even though INR
tended to be lower. The number of bleeding complications tended to be fewer on
vitamin K, but this was not statistically significant (p=0.09).
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Table 1: Changes in warfarin control before and after initiation of vitamin K
supplementation.
Case

No vitamin K

Vitamin K

INR

2.41±1.23

2.94±1.34

(target 1.8-2.0)

(1.2-5.3)

(1.2-4.8)

Warfarin (mg)

3.61±0.91

3.54±1.69

divergence

0.88±1.00

1.23±1.16

INR

1.81±067

1.55±0.20

(target 1.8-2.0)

(1.1-3.5)

(1.3-1.8)

Warfarin (mg)

5.58±1.36

3.84±1.32

divergence

0.57±0.33

0.35±0.20

INR

2.54±0.80

1.92±0.43

(target 1.8-2.5)

(1.7-3.88)

(1.5-2.91)

Warfarin (mg)

1.06±0.40

1.15±0.32

divergence

0.63±0.63

0.44±0.21

INR

3.30±0.93

1.73±0.29

(target 1.5-1.8)

(1.3-4.36)

(1.3-2.57)

Warfarin (mg)

3.56±2.25

4.56±0.37

divergence

1.50±0.80

0.22±0.20

INR

2.27±1.18

1.74±0.50

(target 2.0-2.5)

(1.13-5.09)

(1.32-2.87)

Warfarin (mg)

1.65±1.32

2.00±0.47

divergence

0.98±0.67

0.57±0.19

INR

2.14±1.22

1.91±0.54

(target 2.0-2.2)

(1.28-3.61)

(1.43-3.44)

Warfarin (mg)

0.94±1.04

0.81±0.40

divergence

0.94±0.77

0.49±0.30

Variance
(F-test)

Difference
(t-test)

NS

NS

<0.05

NS

1
NS
<0.001

NS

NS

<0.01

2
<0.05
<0.05

<0.05

NS

NS

3
NS
<0.001

<0.01

<0.001

NS

4

5

<0.01
<0.05

NS

<0.01

NS
<0.05

<0.001

NS

<0.001

NS

6
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Continuous data are expressed as mean ± standard deviation. Target range and
highest and lowest values are shown for INR. Divergence is the difference
between measured INR and median of target INR.

Table 2. Comparison of averages of 6 patients before and after initiation of
vitamin K supplementation.
No vitamin K

Vitamin K

p

Mean

2.41±0.46

1.96±0.45

NS

SD

1.00±0.22

0.55±0.37

<0.05

divergence

0.86±0.78

0.56±0.63

<0.01

Mean

2.73±1.67

2.65±1.41

NS

SD

1.21±0.56

0.76±0.54

NS

0.83±0.69

0.17±0.37

0.09

0

0

-

INR

Warfarin (mg)

Bleeding
Thromboembolic

Continuous data are expressed as mean ± standard deviation. Data of bleeding
and thromboembolic complications are number of events during follow-up
periods.

Discussion
These results all indicate significantly better INR control after initiation of vitamin
K supplementation, which can theoretically lead to fewer complications from INR
out of therapeutic range. Furthermore, the absence of thromboembolic
complication after starting low-dose vitamin K suggests safety of its use even in
patients on an LVAD. The target range for INR in our patients has fluctuated with
time as more data on the risk of pump thrombosis have become available. In
addition, our target range varies between patients based on clinical criteria.
Patients who have had numerous bleeding episodes will usually be assigned a
low INR range, while a higher range will be used in those with heparin induced
thrombocytopenia, atrial fibrillation, documented or suspected hypercoagulable
state, or thromboembolic episodes. Despite the fact that half of our patients had
an average INR below the lower limit of their target range, there was less
divergence between their actual INR and target INR after initiation of vitamin K
supplementation, suggesting better overall control. In addition, there were no
thromboembolic events in any patients during the three-month follow-up period or
since thereafter. Another advantage is that low-dose vitamin K therapy is
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affordable and available over-the-counter, hence it can even be cost-beneficial
by reducing complications and frequency of INR tests. The major limitations of
this study are its retrospective design and relatively small number of cases. A
prospective randomized case-control study with a larger case volume would be
necessary to further validate the effectiveness of vitamin K in patients on LVAD
support.
In conclusion, daily low-dose vitamin K supplementations potentially improve INR
control in LVAD patients with unstable INR without increasing the
thromboembolic complications.
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